LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Начало・Списък с акции・Heron Therapeutics Inc

Heron Therapeutics Inc

Затворен

СекторЗдравеопазване

1.21 -0.82

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.2

Максимум

1.22

Ключови измерители
By Trading Economics
Приходи	15M -3M
Продажби	2.4M 41M
EPS	-0.02
Марж на печалбата	-7.278
Служители	128
EBITDA	13M -792K

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+271.9% upside

Дивиденти
By Dow Jones
Следващи печалби	11.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	12M 230M
Предишно отваряне	2.03
Предишно затваряне	1.21

Настроения в новините

By Acuity

85%

15%

331 / 347 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

2.0001 / 2.42 Подкрепа & съпротива

Heron Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.05.2026 г., 23:47 ч. UTC

Пазарно говорене

Gold Falls on Renewed Inflation Concerns -- Market Talk

10.05.2026 г., 23:44 ч. UTC

Пазарно говорене

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

10.05.2026 г., 23:38 ч. UTC

Пазарно говорене

Oil Rises Amid Signs of Ongoing Middle East Tensions -- Market Talk

10.05.2026 г., 23:14 ч. UTC

Пазарно говорене

Australia's Political Map Continues to Be Redrawn -- Market Talk

10.05.2026 г., 22:22 ч. UTC

Придобивния, сливания и поглъщания

Elevra Lithium: Expects Deal to Close in 1Q FY27

10.05.2026 г., 22:21 ч. UTC

Придобивния, сливания и поглъщания

Elevra Lithium: Expects to Received About $71 Million Before Fees, Taxes in Cash

10.05.2026 г., 22:21 ч. UTC

Придобивния, сливания и поглъщания

Elevra Lithium Agrees to Sell Ewoyaa Lithium Project Stake to Zhejiang Huayou Cobalt

10.05.2026 г., 10:21 ч. UTC

Печалби

Saudi Aramco Profit Jumps Despite War Disrupting Shipping Routes -- WSJ

9.05.2026 г., 06:05 ч. UTC

Печалби

Our Innodata Stock Pick Smashed Earnings Expectations. Stay Long. -- Barrons.com

8.05.2026 г., 23:55 ч. UTC

Печалби

Review & Preview: Still Going Strong -- Barrons.com

8.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

8.05.2026 г., 20:49 ч. UTC

Печалби

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8.05.2026 г., 20:25 ч. UTC

Печалби

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8.05.2026 г., 19:43 ч. UTC

Печалби

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8.05.2026 г., 19:43 ч. UTC

Печалби

Cencosud 1Q Net $115M

8.05.2026 г., 19:20 ч. UTC

Пазарно говорене

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8.05.2026 г., 19:18 ч. UTC

Печалби

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8.05.2026 г., 19:16 ч. UTC

Печалби

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8.05.2026 г., 19:08 ч. UTC

Печалби

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8.05.2026 г., 19:05 ч. UTC

Печалби

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8.05.2026 г., 19:02 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8.05.2026 г., 18:51 ч. UTC

Печалби

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8.05.2026 г., 18:49 ч. UTC

Печалби

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8.05.2026 г., 18:41 ч. UTC

Печалби

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8.05.2026 г., 17:38 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8.05.2026 г., 17:14 ч. UTC

Печалби

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8.05.2026 г., 17:04 ч. UTC

Пазарно говорене

Zcash Caps Off Parabolic Week -- Market Talk

8.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

8.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

8.05.2026 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Heron Therapeutics Inc Прогноза

Ценова цел

By TipRanks

271.9% нагоре

12-месечна прогноза

Среден 4.5 USD 271.9%

Висок 6 USD

Нисък 3 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Heron Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

Купи

Задържане

Продай

Според 2 анализатори, дали борсови рейтинги на Heron Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

2.0001 / 2.42Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Настроение

By Acuity

331 / 347 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.